Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Annette E. Hay, Alli Murugesan, Ashley M. DiPasquale, Tom Kouroukis, Irwindeep Sandhu, Vishal Kukreti, Nizar J. Bahlis, Johan Lategan, Donna E. Reece, John F. Lyons, Joana Sederias, Hao Xu, Jean Powers, Lesley K. Seymour & Tony Reiman. (2016) A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leukemia & Lymphoma 57:6, pages 1463-1466.
Read now
Read now
Jonathan How & Karen Yee. (2012)
ENMD-2076 for hematological malignancies. Expert Opinion on Investigational Drugs 21:5, pages 717-732.
Read now
Read now
Shuhong Zhang & Sherif S Farag. (2011) From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 20:7, pages 1015-1028.
Read now
Read now
Myke R Green, Joseph E Woolery & Daruka Mahadevan. (2011) Update on aurora kinase targeted therapeutics in oncology. Expert Opinion on Drug Discovery 6:3, pages 291-307.
Read now
Read now
Articles from other publishers (35)
Gabriella P. A. de Freitas, Luiz Henrique M. Geraldo, Bruna M. Faria, Soniza Vieira Alves‐Leon, Jorge Marcondes de Souza, Vivaldo Moura‐Neto, Bruno Pontes, Luciana F. Romão & Patrícia P. Garcez. (2022) Centromere protein J is overexpressed in human glioblastoma and promotes cell proliferation and migration. Journal of Neurochemistry 162:6, pages 501-513.
Crossref
Crossref
Nadire Özenver, Sara Abdelfatah, Anette Klinger, Edmond Fleischer & Thomas Efferth. (2020) Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma. Investigational New Drugs 39:2, pages 348-361.
Crossref
Crossref
Hyo Jin Kim & Jongchan Kim. (2021) OTUD6A Is an Aurora Kinase A-Specific Deubiquitinase. International Journal of Molecular Sciences 22:4, pages 1936.
Crossref
Crossref
Erin Mulvey & Jia Ruan. (2020) Biomarker-driven management strategies for peripheral T cell lymphoma. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Meral Beksac, Sevinc Balli & Dilara Akcora Yildiz. (2020) Drug Targeting of Genomic Instability in Multiple Myeloma. Frontiers in Genetics 11.
Crossref
Crossref
Yu Liu, Haocheng Yu, Seungyeul Yoo, Eunjee Lee, Alessandro Laganà, Samir Parekh, Eric E. Schadt, Li Wang & Jun Zhu. (2019) A Network Analysis of Multiple Myeloma Related Gene Signatures. Cancers 11:10, pages 1452.
Crossref
Crossref
Ilyas SahinYawara KawanoRomanos Sklavenitis-PistofidisMichele MoschettaYuji MishimaSalomon ManierAntonio SaccoRuben CarrascoRafael Fonseca, Aldo M. Roccaro, Thomas Witzig & Irene M. Ghobrial. (2019) Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Advances 3:7, pages 995-1002.
Crossref
Crossref
Anke Maes, Eline Menu, Kim De Veirman, Ken Maes, Karin Vanderkerken & Elke De Bruyne. (2017) The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget 8:52, pages 90501-90520.
Crossref
Crossref
Karthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, Lim Soon Thye, Wee Joo Chng, Brigette Ma, Ming Huang Chen, Xiaofei Zhou, Hua Liu, Virginia Kelly & Won Seog Kim. (2015) Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Investigational New Drugs 33:4, pages 942-953.
Crossref
Crossref
Karthik Venkatakrishnan, Xiaofei Zhou, Jeffrey Ecsedy, Diane R. Mould, Hua Liu, Hadi Danaee, Howard Fingert, Robert Kleinfield & Ashley Milton. (2015) Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships. The Journal of Clinical Pharmacology 55:3, pages 336-347.
Crossref
Crossref
Jin Cai, Lili Li, Kwon Ho Hong, Xiaoqing Wu, Junqing Chen, Peng Wang, Meng Cao, Xi Zong & Min Ji. (2014) Discovery of 4-aminoquinazoline—urea derivatives as Aurora kinase inhibitors with antiproliferative activity. Bioorganic & Medicinal Chemistry 22:21, pages 5813-5823.
Crossref
Crossref
Cindy Varga, Jacob Laubach, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson & Paul G. Richardson. (2014) Novel Targeted Agents in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America 28:5, pages 903-925.
Crossref
Crossref
Kevin R. Kelly, Thomas C. Shea, André Goy, Jesus G. Berdeja, Craig B. Reeder, Kevin T. McDonagh, Xiaofei Zhou, Hadi Danaee, Hua Liu, Jeffrey A. Ecsedy, Huifeng Niu, Ely Benaim & Swaminathan Padmanabhan Iyer. (2013) Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investigational New Drugs 32:3, pages 489-499.
Crossref
Crossref
Likun Li, Guang Yang, Chengzhen Ren, Ryuta Tanimoto, Takahiro Hirayama, Jianxiang Wang, David Hawke, Soo Mi Kim, Ju-Seog Lee, Alexei A. Goltsov, Sanghee Park, Michael M. Ittmann, Patricia Troncoso & Timothy C. Thompson. (2012) Glioma pathogenesis‐related protein 1 induces prostate cancer cell death through Hsc70‐mediated suppression of AURKA and TPX2. Molecular Oncology 7:3, pages 484-496.
Crossref
Crossref
Pei-Ying Lee, Chi-Long Chen, Zhong-Zhe Lin, Ann-Lii Cheng, Edmund I-Tsuen Chen, Jacqueline Whang-Peng & Chi-Ying F. Huang. (2013) The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme. Oncology 84:6, pages 326-335.
Crossref
Crossref
Gang Liu, Sunny Abraham, Lan Tran, Troy D. Vickers, Shimin Xu, Michael J. Hadd, Sheena Quiambao, Mark W. Holladay, Helen Hua, Julia M. Ford Pulido, Ruwanthi N. Gunawardane, Mindy I. Davis, Shawn R. Eichelberger, Julius L. Apuy, Dana Gitnick, Michael F. Gardner, Joyce James, Mike A. Breider, Barbara Belli, Robert C. Armstrong & Daniel K. Treiber. (2012) Discovery of Highly Potent and Selective Pan-Aurora Kinase Inhibitors with Enhanced in Vivo Antitumor Therapeutic Index. Journal of Medicinal Chemistry 55:7, pages 3250-3260.
Crossref
Crossref
Benedict Yan & Wee-Joo Chng. 2012. The Centrosome. The Centrosome
255
276
.
Sherif S. Farag. (2011) The potential role of Aurora kinase inhibitors in haematological malignancies. British Journal of Haematology 155:5, pages 561-579.
Crossref
Crossref
Robert P. Evans, Greg Dueck, Roger Sidhu, Sunita Ghosh, Inka Toman, Jonathan Loree, Nizar Bahlis, Alexander C. Klimowicz, Joyce Fung, Michelle Jung, Raymond Lai, Linda M. Pilarski, Andrew R. Belch & Tony Reiman. (2011) Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma. Leukemia Research 35:12, pages 1637-1643.
Crossref
Crossref
Loredana Santo, Teru Hideshima, Diana Cirstea, Madhavi Bandi, Erik A. Nelson, Gullu Gorgun, Scott Rodig, Sonia Vallet, Samantha Pozzi, Kishan Patel, Christine Unitt, Matt Squires, Yiguo Hu, Dharminder Chauhan, Anuj Mahindra, Nikhil C. Munshi, Kenneth C. Anderson & Noopur Raje. (2011) Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide. Clinical Cancer Research 17:10, pages 3259-3271.
Crossref
Crossref
Helen J. Stewart, Lyudmila Kishikova, Fiona L. Powell, Sally P. Wheatley & Timothy J. Chevassut. (2011) The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Experimental Hematology 39:3, pages 330-338.
Crossref
Crossref
Michael E. PrimeStephen M. CourtneyFrederick A. BrookfieldRichard W. MarstonVictoria WalkerJustin WarneAndrew E. BoydNorman A. Kairies, Wolfgang von der Saal, Anja Limberg, Guy Georges, Richard A. Engh, Bernhard Goller, Petra Rueger & Matthias Rueth. (2010) Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase. Journal of Medicinal Chemistry 54:1, pages 312-319.
Crossref
Crossref
Kevin D. Boyd, Faith E. Davies & Gareth J. Morgan. 2011. Multiple Myeloma. Multiple Myeloma
151
187
.
Hiroshi Katayama & Subrata Sen. (2010) Aurora kinase inhibitors as anticancer molecules. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1799:10-12, pages 829-839.
Crossref
Crossref
Jinming Yang, Ryan Splittgerber, Fiona E. Yull, Sara Kantrow, Gregory D. Ayers, Michael Karin & Ann Richmond. (2010) Conditional ablation of Ikkb inhibits melanoma tumor development in mice. Journal of Clinical Investigation 120:7, pages 2563-2574.
Crossref
Crossref
Güllü GörgünElisabetta CalabreseTeru HideshimaJeffrey EcsedyGiulia PerroneMala ManiHiroshi IkedaGiada BianchiYiguo HuDiana CirsteaLoredana SantoYu-Tzu TaiSabikun NaharMei ZhengMadhavi BandiRuben D. CarrascoNoopur Raje, Nikhil Munshi, Paul RichardsonKenneth C. Anderson. (2010) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115:25, pages 5202-5213.
Crossref
Crossref
Joseph M. Negri, Douglas W. McMillin, Jake Delmore, Nicholas Mitsiades, Patrick Hayden, Steffen Klippel, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Carolyn A. Buser, John Pollard, Paul G. Richardson, Kenneth C. Anderson & Constantine S. Mitsiades. (2009)
In vitro
anti‐myeloma activity of the Aurora kinase inhibitor VE‐465
. British Journal of Haematology 147:5, pages 672-676.
Crossref
Crossref
Wee J. Chng & Rafael Fonseca. (2009) Centrosomes and myeloma; Aneuploidy and proliferation. Environmental and Molecular Mutagenesis 50:8, pages 697-707.
Crossref
Crossref
Jui Dutta-Simmons, Yunyu Zhang, Gullu Gorgun, Moshe Gatt, Mala Mani, Teru Hideshima, Kohichi Takada, Nicole E. Carlson, Daniel E. Carrasco, Yu-Tzu Tai, Noopur Raje, Anthony G. Letai, Kenneth C. Anderson & Daniel R. Carrasco. (2009) Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression. Blood 114:13, pages 2699-2708.
Crossref
Crossref
Yuan-Chin Tsai, Haiyan Qi, Chao-Po Lin, Ren-Kuo Lin, John E. Kerrigan, Suzanne G. Rzuczek, Edmond J. LaVoie, Joseph E. Rice, Daniel S. Pilch, Yi Lisa Lyu & Leroy F. Liu. (2009) A G-quadruplex Stabilizer Induces M-phase Cell Cycle Arrest. Journal of Biological Chemistry 284:34, pages 22535-22543.
Crossref
Crossref
John R. PollardMichael Mortimore. (2009) Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents. Journal of Medicinal Chemistry 52:9, pages 2629-2651.
Crossref
Crossref
Dirk HoseThierry RèmeTobias MeissnerJérôme MoreauxAnja SeckingerJoe LewisVladimir BenesAxel BennerMichael HundemerThomas HielscherJohn D. ShaughnessyJrJr, Bart Barlogie, Kai NebenAlwin KrämerJens HillengassUta BertschAnna Jauch, John De VosJean-François RossiThomas MöhlerJonathon BlakeJürgen ZimmermannBernard KleinHartmut Goldschmidt. (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113:18, pages 4331-4340.
Crossref
Crossref
R. Rodriguez-Esteban, P. M. Roberts & M. E. Crawford. (2008) Identifying and classifying biomedical perturbations in text. Nucleic Acids Research 37:3, pages 771-777.
Crossref
Crossref
Christopher D Scharer, Noelani Laycock, Adeboye O Osunkoya, Sanjay Logani, John F McDonald, Benedict B Benigno & Carlos S Moreno. (2008) Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. Journal of Translational Medicine 6:1.
Crossref
Crossref
Florian Nolte & Wolf-K. Hofmann. (2008) Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Annals of Hematology 87:10, pages 777-795.
Crossref
Crossref